- Home
- PHGE vs BGLC Comparison
PHGE vs BGLC Comparison
Compare PHGE & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- BGLC
- Stock Information
- Founded
- PHGE 2015
- BGLC 2017
- Country
- PHGE Israel
- BGLC Malaysia
- Employees
- PHGE N/A
- BGLC N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- BGLC Medical Specialities
- Sector
- PHGE Health Care
- BGLC Health Care
- Exchange
- PHGE Nasdaq
- BGLC Nasdaq
- Market Cap
- PHGE 10.4M
- BGLC 10.7M
- IPO Year
- PHGE N/A
- BGLC N/A
- Fundamental
- Price
- PHGE $0.56
- BGLC $5.34
- Analyst Decision
- PHGE Strong Buy
- BGLC
- Analyst Count
- PHGE 1
- BGLC 0
- Target Price
- PHGE $15.00
- BGLC N/A
- AVG Volume (30 Days)
- PHGE 12.4M
- BGLC 3.1M
- Earning Date
- PHGE 08-13-2025
- BGLC 08-26-2025
- Dividend Yield
- PHGE N/A
- BGLC N/A
- EPS Growth
- PHGE N/A
- BGLC N/A
- EPS
- PHGE N/A
- BGLC N/A
- Revenue
- PHGE N/A
- BGLC $9,265,870.00
- Revenue This Year
- PHGE N/A
- BGLC N/A
- Revenue Next Year
- PHGE N/A
- BGLC N/A
- P/E Ratio
- PHGE N/A
- BGLC N/A
- Revenue Growth
- PHGE N/A
- BGLC N/A
- 52 Week Low
- PHGE $0.34
- BGLC $2.01
- 52 Week High
- PHGE $1.90
- BGLC $15.60
- Technical
- Relative Strength Index (RSI)
- PHGE 57.85
- BGLC 49.57
- Support Level
- PHGE $0.48
- BGLC $5.28
- Resistance Level
- PHGE $0.59
- BGLC $5.85
- Average True Range (ATR)
- PHGE 0.07
- BGLC 0.71
- MACD
- PHGE 0.01
- BGLC -0.12
- Stochastic Oscillator
- PHGE 52.48
- BGLC 20.52
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.